Taking into account possible challenges due to China's corruption crackdown
14/09/23 -"Despite Q1 exceeding expectations, thanks to healthy top-line growth and margin improvements, our target price resets c.10% lower due to potential headwinds related to the Chinese clampdown on ..."
Pages
64
Language
English
Published on
14/09/23
You may also be interested by these reports :
12/09/25
DiaSorin appears to be making significant progress in the testing space. The launch of speciality tests, introduction of the Plex platform, and ...
05/09/25
Bastide reported FY24/25 revenue in line with guidance and our forecast. The more technical business activities remain the primary driver of organic ...
05/09/25
Since we last pushed Philips’ (Buy; Netherlands) investment case in January 2024, its share price performance has been glaringly ahead of the MedTech ...
04/09/25
bioMerieux’s H1 profitability surpassed expectations. Topline growth was driven by robust performance across both segments. However, weakness in ...